Your shopping cart is currently empty

Synonyms: NSC 313680, Fluvermal, Flumoxane, Flumoxanal

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 50 mg | $33 | In Stock | In Stock | |
| 100 mg | $50 | In Stock | In Stock | |
| 500 mg | $88 | In Stock | In Stock | |
| 1 g | $128 | In Stock | In Stock | |
| 5 g | $319 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $45 | In Stock | In Stock |
| Description | Flubendazole (Flumoxane) is available OTC in Europe that is an anthelmintic using to treat worm infection in humans. |
| In vitro | Flubendazole results in morphological changes included contraction of the soma region, the formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus. Flubendazole has a bicyclic ring system in which a benzene has been fused to the -4 and -5 positions of the heterocycle (imidazole). Flubendazole and Albendazole show similar potency in affecting rat embryonic development in vitro, inducing retardation of growth and dysmorphogenic effects at concentrations ≥0.5 μg/mL. |
| In vivo | Flubendazole (6.32 mg/kg/day) initially induces an arrest of embryonic development followed by a generalized cell death that leads to 100% embryolethality by gestation day (GD) 12.5. Flubendazole (3.46 mg/kg/day) markedly reduces embryonic development by GD 12.5 without causing cell death. Flubendazole in olive oil causes a statistically significant increase in embryolethality at doses of 7.83 mg/kg per day and higher, with complete resorption in all dams at 31.33 mg/kg per day in rats. Flubendazole treatment causes a slight increase of metyrapone and daunorubicin activities in hepatic as well as intestinal cytosol in birds. Flubendazole treatment leads to statistically significant inhibition of intestinal GST activity. Flubendazole treatment leads to slight but significant inhibition (decrease to 69%) of 7-ethoxyresorufin activity in hepatic microsomes. |
| Synonyms | NSC 313680, Fluvermal, Flumoxane, Flumoxanal |
| Molecular Weight | 313.28 |
| Formula | C16H12FN3O3 |
| Cas No. | 31430-15-6 |
| Smiles | C(=O)(C=1C=C2C(N=C(NC(OC)=O)N2)=CC1)C3=CC=C(F)C=C3 |
| Relative Density. | 1.444 g/cm3 |
| Storage | Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10.5 mg/mL (33.52 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.05 mg/mL (3.35 mM), Solution. 10% DMSO+90% Saline: < 1.05 mg/mL (3.35 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.